Insulin-like growth factor-I receptor - a potential therapeutic target in medulloblastomas.
Medulloblastomas represent nearly 25% of all paediatric intracranial neoplasms. These highly malignant tumours arise from the cerebellum and affect predominantly children between the ages of 5 and 15. Although the aetiology of medulloblastomas has not been elucidated, several reports show that the insulin-like growth factor-I (IGF-I) signalling system is highly activated in medulloblastoma cell lines, medulloblastoma animal models and medulloblastoma biopsies, suggesting its contribution to the development and/or progression of these tumours. In addition, reports from multiple laboratories confirm a critical role for the IGF-I receptor (IGF-IR) in the process of cellular transformation. Taken together, these observations prompt the investigation of different strategies to impair the function of IGF-IR as a potential therapeutic tool, which by compromising growth and survival of medulloblastoma cells could supplement conventional therapeutic regiments against these malignant neoplasms of childhood.
Reiss
Krzysztof
K
D000293:Adolescent; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002471:Cell Transformation, Neoplastic / Q000187:drug effects; D002528:Cerebellar Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000821:virology; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007577:JC Virus / Q000472:pathogenicity; D008527:Medulloblastoma / Q000188:drug therapy* / Q000378:metabolism / Q000821:virology; D051379:Mice; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000502:physiology; D027601:Polyomavirus Infections / Q000188:drug therapy; D017526:Receptor, IGF Type 1 / Q000037:antagonists & inhibitors* / Q000502:physiology; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D014412:Tumor Virus Infections / Q000188:drug therapy
D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D017526:Receptor, IGF Type 1